Ausgabe 2/2015
Inhalt (23 Artikel)
Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives
Joan Minguet, Katherine H. Smith, Carsten P. Bramlage, Peter Bramlage
Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer
Fadi S. Farhat, Marwan G. Ghosn, Joseph G. Kattan
Pharmacokinetic drug–drug interaction assessment of peptibody trebananib in combination with chemotherapies
Benjamin Wu, Rebeca Melara, Erik Rasmussen, Lei Zhou, Teresa Wong, Cindy Kitahara, Mark Ma, Jessica Lu, Erick Gamelin, Cheryl A. Pickett, Yu-Nien Sun
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703
Kenichiro Kudo, Katsuyuki Hotta, Eiki Ichihara, Hiroshige Yoshioka, Kei Kunimasa, Kazuya Tsubouchi, Masahiro Iwasaku, Yuka Kato, Isao Oze, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma
Mi Na Kim, Simon Weonsang Ro, Do Young Kim, Da Young Kim, Kyung-Ju Cho, Jeon Han Park, Ho Yeong Lim, Kwang-Hyub Han
Elemental diet moderates 5-fluorouracil-induced gastrointestinal mucositis through mucus barrier alteration
Rei Kawashima, Fumitaka Kawakami, Tatsunori Maekawa, Hajime Yamamoto, Wasaburo Koizumi, Takafumi Ichikawa
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer
Shinya Ueda, Hisato Kawakami, Shinichi Nishina, Tsutomu Sakiyama, Yoshikane Nonagase, Takafumi Okabe, Takao Tamura, Kazuhiko Nakagawa
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4–p53 interaction
Susan M. Christner, Dana M. Clausen, Jan H. Beumer, Robert A. Parise, Jianxia Guo, Yijun Huang, Alexander S. Dömling, Julie L. Eiseman
Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist
Taisuke Ezaki, Takeo Kosaka, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Akira Miyajima, Mototsugu Oya
Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway
Hongyan Wu, Fangtian Fan, Zhaoguo Liu, Cunsi Shen, Aiyun Wang, Yin Lu
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer
Rory J. Makielski, Sam J. Lubner, Daniel L. Mulkerin, Anne M. Traynor, David Groteluschen, Jens Eickhoff, Noelle K. LoConte
Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse
Fumiaki Yamashita, Ikumi Komoto, Hiroaki Oka, Keizo Kuwata, Mayuko Takeuchi, Fumio Nakagawa, Kunihiro Yoshisue, Masato Chiba
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study
Shoji Nagao, Shin Nishio, Satoshi Okada, Takeo Otsuki, Kiyoshi Fujiwara, Hiroshi Tanabe, Masashi Takano, Yoko Hasumi, Yuji Takei, Tetsuya Hasegawa, Takashi Matsumoto, Keiichi Fujiwara, Munetaka Takekuma, Kazuto Nakamura, Muneaki Shimada, Mitsuaki Suzuki, Junzo Kigawa
Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363
James W. T. Yates, Phillippa Dudley, Jane Cheng, Celina D’Cruz, Barry R. Davies
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis
Motoo Nomura, Isao Oze, Tetsuya Abe, Azusa Komori, Yukiya Narita, Toshiki Masuishi, Hiroya Taniguchi, Shigenori Kadowaki, Takashi Ura, Masashi Andoh, Ryosuke Kawai, Norihisa Uemura, Makoto Ishihara, Tsutomu Tanaka, Masahiro Tajika, Yasumasa Niwa, Kei Muro, Manabu Muto
Population pharmacokinetics of kahalalide F in advanced cancer patients
Bernardo Miguel-Lillo, Belén Valenzuela, José Esteban Peris-Ribera, Arturo Soto-Matos, Juan José Pérez-Ruixo
Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy
Yasuhiro Mitsui, Yasushi Sato, Hiroshi Miyamoto, Yasuteru Fujino, Toshi Takaoka, Jinsei Miyoshi, Miwako Kagawa, Hiroyuki Ohnuma, Masahiro Hirakawa, Tomohiro Kubo, Takahiro Osuga, Tamotsu Sagawa, Yasuhiro Sato, Yasuo Takahashi, Shinich Katsuki, Toshinori Okuda, Rishu Takimoto, Masayoshi Kobune, Takayuki Nobuoka, Koichi Hirata, Junji Kato, Tetsuji Takayama
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells
Johannes Kraus, Marianne Kraus, Nora Liu, Lenka Besse, Jürgen Bader, Paul P. Geurink, Gerjan de Bruin, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer
Clarinda Chua, Iain Beehuat Tan, Yasuhide Yamada, Sun Young Rha, Wei Peng Yong, Whee Sze Ong, Chee Kian Tham, Matthew Ng, David W. M. Tai, Satoru Iwasa, Hwee Yong Lim, Su-Pin Choo
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
Toshihiko Doi, Kenji Tamura, Yuko Tanabe, Kan Yonemori, Takayuki Yoshino, Nozomu Fuse, Makoto Kodaira, Hideaki Bando, Kazuo Noguchi, Takashi Shimamoto, Atsushi Ohtsu
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
Ursula Matulonis, Suzanne Berlin, Hang Lee, Christin Whalen, Elizabeth Obermayer, Richard Penson, Joyce Liu, Susana Campos, Carolyn Krasner, Neil Horowitz
Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma
Pascal Chastagner, Bénédicte Devictor, Birgit Geoerger, Isabelle Aerts, Pierre Leblond, Didier Frappaz, Jean-Claude Gentet, Serge Bracard, Nicolas André
Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?
Letizia Porcelli, Gabriella Guida, Stefania Tommasi, Michele Guida, Amalia Azzariti